NZ582056A - Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation - Google Patents
Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activationInfo
- Publication number
- NZ582056A NZ582056A NZ582056A NZ58205608A NZ582056A NZ 582056 A NZ582056 A NZ 582056A NZ 582056 A NZ582056 A NZ 582056A NZ 58205608 A NZ58205608 A NZ 58205608A NZ 582056 A NZ582056 A NZ 582056A
- Authority
- NZ
- New Zealand
- Prior art keywords
- carboxamide
- indole
- compounds
- pyrimidin
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Disclosed are compounds of formula Ia, salts and hydrates thereof, and methods for their preparation, where: U and Z1-Z4 are C or N RA comprises a substituted heteroaryl attached to the core structure through a linker moiety Specific examples of compounds of formula Ia include: N-(adamantan-1-ylmethyl)-1-pyrimidin-2-yl-1H-indole-3-carboxamide, N-{ [1-(4-methoxyphenyl)cyclohexyl]methyl} -1-pyrimidin-2-yl-4-(trifluoromethyl)-1H-indole-3-carboxamide, N-[2-(4-chlorophenyl)-2-piperidin-lylethyl]-4-fluoro-1-pyrimidin-2-yl-1H-indole-3-carboxamide, and N-[2-(4-chlorophenyl)-2-piperidin-1-ylethyl]-1-(3-cyanopyridin-2-yl)-4-methyl-1H-indole-3-carboxamide. Compounds of formula Ia are useful for treating a condition responsive to pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder, steoarthritis, rheumatoid arthritis, arthrosclerosis, glaucoma, irritable bowel syndrome, inflammatory bowel disease, cirrhosis, lupus, scleroderma, Alzheimer's disease, traumatic brain injury, asthma, chronic obstructive pulmonary disease, or interstitial fibrosis..
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95525007P | 2007-08-10 | 2007-08-10 | |
PCT/US2008/072760 WO2009023623A1 (en) | 2007-08-10 | 2008-08-11 | Heteroaryl amide analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ582056A true NZ582056A (en) | 2012-08-31 |
Family
ID=40351102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ582056A NZ582056A (en) | 2007-08-10 | 2008-08-11 | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2185560A4 (en) |
JP (2) | JP2010535816A (en) |
KR (1) | KR20100066422A (en) |
CN (1) | CN101778850A (en) |
AU (1) | AU2008286946B2 (en) |
BR (1) | BRPI0812594A2 (en) |
CA (1) | CA2691512A1 (en) |
CO (1) | CO6251319A2 (en) |
EA (1) | EA020332B1 (en) |
IL (1) | IL202550A0 (en) |
NZ (1) | NZ582056A (en) |
SG (1) | SG183699A1 (en) |
UA (1) | UA99729C2 (en) |
WO (1) | WO2009023623A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2243772T1 (en) * | 2009-04-14 | 2012-05-31 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
WO2012110190A1 (en) * | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
EP2707101B1 (en) * | 2011-05-12 | 2019-02-13 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
WO2012163456A1 (en) * | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) * | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
JP5955957B2 (en) | 2011-07-22 | 2016-07-20 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as P2X7 receptor antagonists |
EA024204B1 (en) | 2012-01-20 | 2016-08-31 | Актелион Фармасьютиклз Лтд. | Heterocyclic amide derivatives as p2xreceptor antagonists |
JOP20130213B1 (en) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | 5-ht3 receptor antagonists |
CA2890886C (en) | 2012-12-12 | 2020-10-27 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
JP6282016B2 (en) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Heterocyclic amide derivatives as P2X7 receptor antagonists |
CN104918946B (en) * | 2013-01-22 | 2017-03-29 | 埃科特莱茵药品有限公司 | As P2X7The heterocyclic amide derivative of receptor antagonist |
CN105121439A (en) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
JO3773B1 (en) * | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | P2x7 modulators |
ES2689526T3 (en) | 2013-03-14 | 2018-11-14 | Janssen Pharmaceutica Nv | P2X7 modulators |
US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
TWI627174B (en) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | P2x7 modulators |
ES2644025T3 (en) * | 2013-07-17 | 2017-11-27 | Global Alliance For Tb Drug Development | Azaindole compounds, synthesis thereof, and methods of use thereof |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
JP6713982B2 (en) | 2014-07-24 | 2020-06-24 | ファイザー・インク | Pyrazolopyrimidine compounds |
PE20170295A1 (en) | 2014-08-06 | 2017-03-30 | Pfizer | IMIDAZOPYRIDAZINE COMPOUNDS |
US10150766B2 (en) | 2014-09-12 | 2018-12-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
WO2016053947A1 (en) | 2014-09-29 | 2016-04-07 | Takeda Pharmaceutical Company Limited | Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide |
CN107207476B (en) * | 2014-12-15 | 2021-03-19 | 默克专利有限公司 | Indole and azaindole derivatives and their use in neurodegenerative diseases |
JP6462493B2 (en) | 2015-05-29 | 2019-01-30 | 株式会社デンソー | Approach determination device, approach determination method |
CN108602775B (en) | 2016-01-14 | 2022-04-29 | 贝思以色列女会吏医学中心公司 | Mast cell modulators and uses thereof |
TW201819361A (en) | 2016-09-03 | 2018-06-01 | 印度商托仁特生技有限公司 | Novel indazole compounds |
TW202028198A (en) | 2018-09-28 | 2020-08-01 | 比利時商健生藥品公司 | Monoacylglycerol lipase modulators |
MX2021003661A (en) | 2018-09-28 | 2021-08-19 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators. |
CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
KR20220157999A (en) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | monoacylglycerol lipase modulator |
WO2022062991A1 (en) * | 2020-09-22 | 2022-03-31 | 苏州恩华生物医药科技有限公司 | Indole derivatives and use thereof |
WO2023198199A1 (en) * | 2022-04-15 | 2023-10-19 | 先声再明医药有限公司 | Myt1 kinase inhibitor |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2557342A1 (en) * | 1975-12-19 | 1977-06-30 | Hoechst Ag | BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
DE2931323A1 (en) * | 1979-08-02 | 1981-02-26 | Kali Chemie Pharma Gmbh | NEW N-AMINOALKYLINDOL DERIVATIVES AND THEIR SALTS |
DE3131527A1 (en) * | 1981-08-08 | 1983-02-24 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 1-PHENYL-2-AMINOCARBONYLINDOL COMPOUNDS AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US5023265A (en) * | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
TW229140B (en) * | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
CZ298827B6 (en) * | 1997-12-24 | 2008-02-20 | Sanofi - Aventis Deutschland GmbH | IIndole derivatives as inhibitors of Xa factor, process of their preparation and pharmaceutical composition in which they are comprised |
RU2254333C2 (en) * | 1999-04-09 | 2005-06-20 | Астразенека Аб | Derivatives of adamantane, method for their preparing, pharmaceutical composition based on thereof and methods for treatment |
WO2001025220A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
CA2399791A1 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
WO2002012189A1 (en) * | 2000-08-09 | 2002-02-14 | Mitsubishi Pharma Corporation | Fused bicyclic amide compounds and medicinal use thereof |
JP4529119B2 (en) * | 2001-08-09 | 2010-08-25 | 小野薬品工業株式会社 | Carboxylic acid derivative compound and drug containing the compound as an active ingredient |
EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
JP4390704B2 (en) * | 2002-10-03 | 2009-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | Indole-3-carboxamide as glucokinase (GK) activator |
DE10253426B4 (en) * | 2002-11-15 | 2005-09-22 | Elbion Ag | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and methods for their preparation |
AU2003303217A1 (en) * | 2002-12-20 | 2004-07-14 | Bayer Healthcare Ag | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
FR2857966A1 (en) * | 2003-07-24 | 2005-01-28 | Aventis Pharma Sa | New piperazine and tetrahydropyridine derivatives are tubulin polymerization inhibitors used for treating cancer and disaggregating cell masses derived from vascular tissue |
SE0302192D0 (en) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
FR2874015B1 (en) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | N- (1H-INDOLYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2880625B1 (en) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
TW200700387A (en) * | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
FR2888847B1 (en) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | N- (HETERIARYL) -1-HETEORARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION |
US20070213359A1 (en) * | 2005-12-30 | 2007-09-13 | Acadia Pharmaceuticals Inc. | Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof |
WO2007098214A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
-
2008
- 2008-08-11 CA CA002691512A patent/CA2691512A1/en not_active Abandoned
- 2008-08-11 KR KR1020097026704A patent/KR20100066422A/en not_active Application Discontinuation
- 2008-08-11 CN CN200880021498A patent/CN101778850A/en active Pending
- 2008-08-11 UA UAA200913336A patent/UA99729C2/en unknown
- 2008-08-11 JP JP2010520343A patent/JP2010535816A/en not_active Ceased
- 2008-08-11 EA EA200971085A patent/EA020332B1/en not_active IP Right Cessation
- 2008-08-11 AU AU2008286946A patent/AU2008286946B2/en not_active Ceased
- 2008-08-11 NZ NZ582056A patent/NZ582056A/en not_active IP Right Cessation
- 2008-08-11 BR BRPI0812594-5A patent/BRPI0812594A2/en not_active IP Right Cessation
- 2008-08-11 WO PCT/US2008/072760 patent/WO2009023623A1/en active Application Filing
- 2008-08-11 SG SG2012058533A patent/SG183699A1/en unknown
- 2008-08-11 EP EP08797591A patent/EP2185560A4/en not_active Withdrawn
-
2009
- 2009-12-06 IL IL202550A patent/IL202550A0/en unknown
- 2009-12-22 CO CO09146587A patent/CO6251319A2/en not_active Application Discontinuation
-
2014
- 2014-11-25 JP JP2014238138A patent/JP2015110566A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BRPI0812594A2 (en) | 2015-06-23 |
EP2185560A4 (en) | 2011-10-05 |
UA99729C2 (en) | 2012-09-25 |
SG183699A1 (en) | 2012-09-27 |
CA2691512A1 (en) | 2009-02-19 |
CN101778850A (en) | 2010-07-14 |
WO2009023623A1 (en) | 2009-02-19 |
JP2010535816A (en) | 2010-11-25 |
JP2015110566A (en) | 2015-06-18 |
AU2008286946A1 (en) | 2009-02-19 |
EA200971085A1 (en) | 2010-06-30 |
KR20100066422A (en) | 2010-06-17 |
CO6251319A2 (en) | 2011-02-21 |
EP2185560A1 (en) | 2010-05-19 |
EA020332B1 (en) | 2014-10-30 |
IL202550A0 (en) | 2010-06-30 |
AU2008286946B2 (en) | 2013-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ582056A (en) | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation | |
NL1026958C2 (en) | Aryl or heteroarylamide compounds. | |
CA2645257C (en) | Sulfonyl benzimidazole derivatives | |
JP4054368B2 (en) | Substituted methylaryl or heteroarylamide compounds | |
US10005731B2 (en) | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
CN1592744A (en) | Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity | |
KR101507717B1 (en) | Substituted acetophenones useful as PDE4 inhibitors | |
WO2000075113A1 (en) | Novel heterocyclic carboxamide derivatives | |
NZ573832A (en) | N-(4-{ 2-[4-aryl-piperazin-1-yl]ethyl} cyclohexyl)-acetamide derivatives for the treatment of neuropsychiatric disorders | |
NO20054206L (en) | biphenyl | |
WO2006023460A3 (en) | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | |
TWI360540B (en) | Tetrahydroisoquinolylsulphonamide derivatives, the | |
JP2008537741A5 (en) | ||
JP2005526798A (en) | Heteroaromatic urea derivatives as VR-1 receptor modulators for the treatment of pain | |
SK4799A3 (en) | Use of non-peptidic n3 antagonists for producing pharmaceutical compositions | |
CN1671377A (en) | 1H-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-CB receptor ligands | |
EP1437351A1 (en) | Amine derivative | |
JP2010507664A (en) | Benzimidazole compounds | |
WO2008130616A3 (en) | Diaryl morpholines as cb1 modulators | |
JP2013500306A (en) | Dihydropyrimidone amides as P2X7 modulators | |
KR20160055181A (en) | Novel Quinolinone Derivatives and Uses Thereof | |
EP1838663B1 (en) | Glycine transport inhibitors | |
NO20082919L (en) | Heterosubstituted 3-alkylazetidine derivatives | |
JP2011519845A5 (en) | ||
JP2016528274A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2015 BY SPRUSON + FERGUSON Effective date: 20130103 |
|
LAPS | Patent lapsed |